A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

April 1, 2017

Primary Completion Date

November 19, 2019

Study Completion Date

November 19, 2019

Conditions
Rheumatoid Arthritis
Interventions
DRUG

YRA-1909 low dose

A low dose of YRA-1909; daily oral intake for 12 weeks

DRUG

YRA-1909 mid dose

A mid dose of YRA-1909; daily oral intake for 12 weeks

DRUG

YRA-1909 high dose

A high dose of YRA-1909; daily oral intake for 12 weeks

DRUG

Placebo

Matching placebo dosing with daily oral intake for 12 weeks

Trial Locations (14)

110744

Seoul National University Hospital, Seoul

Unknown

Hanllym University Medical Center, Anyang

Chungbuk National University Hospital, Chungju

Kelmyung University Dongsan Medical Center, Daegu

Chungnam National University Hospital, Daejeon

Kyung Hee University Hospital at Gangdong, Gangdong

Chonnam National University Hospital, Gwangju

Gachon University Gil Medical Center, Incheon

Chonbuk National University Hospital, Jeonju

Seoul National University Bundang Hospital, Seongnam

Hanyang University Seoul Hospital, Seoul

KyungHee University Hospital, Seoul

Seoul Metropolitan Goverment Seoul National Univeersity Boramae Medical Center, Seoul

Ajou University Hospital, Suwon

All Listed Sponsors
lead

Yungjin Pharm. Co., Ltd.

INDUSTRY

NCT03275025 - A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter